Product Code: ETC7543073 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 India Fabrys Disease Treatment Market Overview |
3.1 India Country Macro Economic Indicators |
3.2 India Fabrys Disease Treatment Market Revenues & Volume, 2021 & 2031F |
3.3 India Fabrys Disease Treatment Market - Industry Life Cycle |
3.4 India Fabrys Disease Treatment Market - Porter's Five Forces |
3.5 India Fabrys Disease Treatment Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
3.6 India Fabrys Disease Treatment Market Revenues & Volume Share, By Medication, 2021 & 2031F |
4 India Fabrys Disease Treatment Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness about Fabry's disease in India |
4.2.2 Growth in healthcare infrastructure and facilities |
4.2.3 Rising healthcare expenditure and improving access to treatment |
4.2.4 Technological advancements in Fabry's disease treatment |
4.2.5 Supportive government initiatives and policies related to rare disease treatment |
4.3 Market Restraints |
4.3.1 High treatment costs and limited affordability for some patients |
4.3.2 Limited availability of specialized healthcare professionals |
4.3.3 Lack of early diagnosis and screening programs |
4.3.4 Regulatory challenges in drug approval and market access |
4.3.5 Limited research and development in Fabry's disease treatments specific to the Indian population |
5 India Fabrys Disease Treatment Market Trends |
6 India Fabrys Disease Treatment Market, By Types |
6.1 India Fabrys Disease Treatment Market, By Distribution Channel |
6.1.1 Overview and Analysis |
6.1.2 India Fabrys Disease Treatment Market Revenues & Volume, By Distribution Channel, 2021- 2031F |
6.1.3 India Fabrys Disease Treatment Market Revenues & Volume, By E-commerce, 2021- 2031F |
6.1.4 India Fabrys Disease Treatment Market Revenues & Volume, By Drug Store and Pharmacies, 2021- 2031F |
6.1.5 India Fabrys Disease Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.2 India Fabrys Disease Treatment Market, By Medication |
6.2.1 Overview and Analysis |
6.2.2 India Fabrys Disease Treatment Market Revenues & Volume, By Agalsidase beta, 2021- 2031F |
6.2.3 India Fabrys Disease Treatment Market Revenues & Volume, By Agalsidase Alpha, 2021- 2031F |
6.2.4 India Fabrys Disease Treatment Market Revenues & Volume, By Migalstat, 2021- 2031F |
6.2.5 India Fabrys Disease Treatment Market Revenues & Volume, By Antihistamines, 2021- 2031F |
6.2.6 India Fabrys Disease Treatment Market Revenues & Volume, By Others, 2021- 2031F |
7 India Fabrys Disease Treatment Market Import-Export Trade Statistics |
7.1 India Fabrys Disease Treatment Market Export to Major Countries |
7.2 India Fabrys Disease Treatment Market Imports from Major Countries |
8 India Fabrys Disease Treatment Market Key Performance Indicators |
8.1 Number of patients diagnosed with Fabry's disease annually |
8.2 Adoption rate of advanced treatment options in Fabry's disease |
8.3 Patient satisfaction and quality of life improvement post-treatment |
8.4 Number of healthcare facilities offering specialized care for Fabry's disease |
8.5 Rate of early diagnosis and screening programs implemented for Fabry's disease |
9 India Fabrys Disease Treatment Market - Opportunity Assessment |
9.1 India Fabrys Disease Treatment Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
9.2 India Fabrys Disease Treatment Market Opportunity Assessment, By Medication, 2021 & 2031F |
10 India Fabrys Disease Treatment Market - Competitive Landscape |
10.1 India Fabrys Disease Treatment Market Revenue Share, By Companies, 2024 |
10.2 India Fabrys Disease Treatment Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |